Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 August 2020 | Story Andre Damons | Photo Supplied
Max du Preez, Editor: Vrye Weekblad (top left), was the facilitator was the facilitator for Thursday’s UFS Though-Leader webinar that included Prof Salim Abdool Karim, Director: Centre for the AIDS Programme of Research in South Africa (CAPRISA) and Chair: South African Ministerial Advisory Committee on COVID-19 (top right); Prof Glenda Gray, President and CEO: South African Medical Research Council (SAMRC) (bottom left); and Prof Felicity Burt from the UFS and NRF-DST South African Research Chair in Vector-borne and Zoonotic Pathogens Research (bottom right), participated in Thursday’s Though-Leader webinar.

Although the decline in COVID-19 cases is a promising sign for South Africa, there are concerns about a second surge, and the country should not become complacent.

This was the opinion of the three experts who took part in the first Thought-Leader webinar presented by the University of the Free State (UFS) on Thursday, 13 August. The 2020 UFS Thought-Leader Webinar Series, themed 'Post-COVID-19, Post-Crisis', is taking place in collaboration with Vrye Weekblad as part of the Vrystaat Literature Festival’s online initiative, VrySpraak-digitaal.

The panellists included top experts such as Prof Salim Abdool Karim, Director: Centre for the AIDS Programme of Research in South Africa (CAPRISA) and Chair: South African Ministerial Advisory Committee on COVID-19; Prof Glenda Gray, President and CEO: South African Medical Research Council (SAMRC); and the UFS’ Prof Felicity Burt, NRF-DST South African Research Chair in Vector-borne and Zoonotic Pathogens Research.
Prof Karim said the downward decline is consistent and the number of patients presenting at hospitals is also declining.
 
Promising trend of decline
“What we are seeing is a promising trend, and it looks like we are on the decline. A question that I am often asked is: Is the worst over? The answer is not clear-cut. We are concerned about the risk of a second surge. If anything – what really concerns me at this stage is a second surge, as I think about how the pandemic may play out over the next few weeks,” said Prof Karim. 

He also referred to countries such as the US, Spain, New Zealand, Vietnam, and South Korea, which are now facing a second surge. 

“We need to be very careful; this is not the time for complacency. We need to maintain all our efforts. If we look at one of the key drivers, it is the need for our economy to restart. We need to get people back to work,” said Prof Karim. 
According to him, we have to look at COVID-19 not as a sprint, but as a marathon. “As we learn to co-exist with this virus, aim for containment; we need to plan for the long term. Even if we get a vaccine, it is unlikely that we will be able to vaccinate a substantial part of our population before the end of next year.” 

“We need to transition from being scared to a situation where we can control our risk. When we know that we can control the risk and then influence the risk, we influence the risk of everyone around us. Part of the new normal is the strategy of mitigation with prevention, plus preventing outbreaks.”

Schools and vaccine development
Prof Gray spoke about whether schools should be open and the role that children play in transmission, how to avoid the second wave, how to adjust our testing, and the exciting news around vaccine development. 

As a paediatrician and a parent, Prof Gray said she believes schools should open. “Children have a different immune response to COVID-19. They have different immune responses to Coronavirus and they probably have less viral-load copies which makes them have milder diseases. They are lucky to have been spared from symptomatic or severe disease,” said Prof Gray. 

According to her, schools need to be de-risked as much as possible, with children and teachers wearing masks, washing hands, making sure that there is good ventilation in the school and that windows are wide open. 

“We also need to know about the comorbidity and ages of teachers, so that we can keep the sick and older teachers out of direct contact. The younger teachers with no comorbidities should be teaching. 

“We also know from our experiences with health workers that transmissions happen in the tearoom where teachers take off their masks and talk. We need to minimise the transmissions in tearooms and protect teachers and parents who are older and have comorbidities.”  

Prof Gray said from data she has seen, schools play a very small role in the transmission of COVID-19; a lot more (transmissions) happen in the community, by commuting, and overcrowded taxis.

Prof Gray agreed with Prof Karim that we should be concerned about a second wave, and that we need to make sure community transmissions are minimised. 

Regarding a vaccine, Prof Gray said a global race is on to find a vaccine. “The more vaccines the better, we want more vaccines to work. The more vaccines, the more affordable they are, and the more doses are available.”

One health approach

During her presentation, Prof Burt said the current response to outbreaks is largely reactive rather than proactive, and “if we have more of a one-health approach, with forecasting, early detection, and a more rapid response, we could have an impact on public health in the future”. 


News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept